Tyropanoic Acid

Summary

Tyropanoic Acid (CHEMBL1201261) is an approved small molecule (ATC V08AC09).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AC09
• Chemistry: 641.02 Da · C15H18I3NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201261
Name	Tyropanoic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5611
ATC	V08AC09
Molecular formula	C15H18I3NO3
Molecular weight	641.02
InChIKey	YMOXVLQZFAUUKI-UHFFFAOYSA-N

SMILES: CCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)O)I)I

IUPAC name: 2-[[3-(butanoylamino)-2,4,6-triiodophenyl]methyl]butanoic acid

Also known as: Tyropanic acid, Tyropanoic acid, TYROPANOIC ACID

Parent form; salt/anhydrous children: CHEMBL1200899

Patent coverage: 57 distinct patent families (139 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).